EUVIMEDEUVIMED entdecken
Open Access

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma

Vandana Batra, Ajami Gikandi iD, Bruce Pawel, Daniel Martinez, M Meaghan Granger, Araz Marachelian iD, Julie R Park, John M Maris iD, Kieuhoa T Vo iD, Katherine K Matthay iD, Steven G DuBois iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30743 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Vandana Batra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: 3-Iodobenzylguanidine, Neuroblastoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prior studies suggest that norepinephrine transporter (NET) and vesicular monoamine transporter 2 (VMAT2) mediate meta‐iodobenzylguanidine (MIBG) uptake and retention in neuroblastoma tumors. We evaluated the relationship between NET and VMAT2 tumor expression and clinical response to 131 I‐MIBG therapy in patients with neuroblastoma.

Methods

Immunohistochemistry (IHC) was used to evaluate NET and VMAT2 protein expression levels on archival tumor samples (obtained at diagnosis or relapse) from patients with relapsed or refractory neuroblastoma treated with 131 I‐MIBG. A composite protein expression H ‐score was determined by multiplying a semi‐quantitative intensity value (0–3+) by the percentage of tumor cells expressing the protein.

Results

Tumor samples and clinical data were available for 106 patients, of whom 28.3% had partial response (PR) or higher. NET H ‐score was not significantly associated with response (≥PR), though the percentage of tumor cells expressing NET was lower among responders (median 80% for ≥PR vs. 90% for

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

3-IodobenzylguanidineNeuroblastomaHumansNorepinephrine Plasma Membrane Transport ProteinsVesicular Monoamine Transport ProteinsRadiopharmaceuticalsN-Myc Proto-Oncogene ProteinNeoplasm Recurrence, LocalChronic Disease

Stichwörter der Autor:innen

131I-MIBGbiomarkerneuroblastomanorepinephrine transportervesicular monoamine transporter 2

Substanzen

3-IodobenzylguanidineNorepinephrine Plasma Membrane Transport ProteinsVesicular Monoamine Transport ProteinsRadiopharmaceuticalsN-Myc Proto-Oncogene Protein

Autor:innen und Institutionen

  • Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pathology, Children's Hospital Los Angeles and USC Keck School of Medicine, Los Angeles, California, USA.
  • Department of Pediatrics, Cook Children's Hospital, Fort Worth, Texas, USA.
  • Department of Pediatrics, Children's Hospital Los Angeles and USC Keck School of Medicine, Los Angeles, California, USA.
  • Department of Pediatrics, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, Washington, USA.

ORCID-Profile: Ajami Gikandi, Araz Marachelian, John M Maris, Kieuhoa T Vo, Katherine K Matthay, Steven G DuBois

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Batra, V., Gikandi, A., Pawel, B., Martinez, D., Granger, M. M., Marachelian, A., Park, J. R., Maris, J. M., Vo, K. T., Matthay, K. K., & DuBois, S. G. (2024). Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30743

Vancouver

Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, et al. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30743

BibTeX
@article{Batra2024,
  author = {Batra, Vandana and Gikandi, Ajami and Pawel, Bruce and Martinez, Daniel and Granger, M Meaghan and Marachelian, Araz and Park, Julie R and Maris, John M and Vo, Kieuhoa T and Matthay, Katherine K and DuBois, Steven G},
  title = {Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30743}
}
Kostenlos starten →